MedTrace Logo

Prevalence and Risk Factors of Metabolic-Associated Hepatic Steatosis in Individuals Living With Type 1 Diabetes

NCT07475962 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2026-03-23

No results posted yet for this study

Summary

The goal of this observational cross-sectional study is to assess the prevalence and stage of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), specifically liver steatosis and fibrosis in adults aged 18 and older living with type 1 diabetes or Latent Autoimmune Diabetes in Adults (LADA) in Quebec.

The main questions it aims to answer are:

1. What is the prevalence and severity of liver steatosis and fibrosis among people living with type 1 diabetes in Québec?
2. Are there patients with type 1 diabetes who have advanced, undiagnosed stages of liver disease that require management but are missed by current standard care practices?

Researchers will compare three participant subgroups based on adiposity (a control group without increased adiposity, an overweight group with increased adiposity, and an obesity group with increased adiposity) to see if the prevalence and severity of hepatic steatosis and fibrosis are highest in the obesity group and lowest in the control group. They will also explore if variables and potential risk factors associated with liver disease differ across these subgroups.

Participants will attend a single study visit where they will be asked to:

* Provide clinical data through laboratory analyses.
* Undergo specific clinical procedures.
* Complete validated questionnaires.

Conditions

  • Type 1 Diabetes
  • Liver Steatoses
  • MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
  • Liver Fibrosis
  • Latent Autoimmune Diabetes in Adult (LADA)

Interventions

OTHER

Adiposity and BMI Classification

Participants are classified into three subgroups based on their BMI and the presence of increased adiposity. Increased adiposity is defined by waist circumference, waist-to-hip ratio, or waist-to-height ratio exceeding sex- and ethnicity-specific thresholds. The subgroups are: a control group (no increased adiposity), an overweight group (BMI 25.0-29.9 kg/m² with increased adiposity), and an obesity group (BMI ≥ 30 kg/m² with increased adiposity).

Sponsors & Collaborators

  • Institut de Recherches Cliniques de Montreal

    lead OTHER

Principal Investigators

  • Sarah Béland-Bonenfant, M.D. Ph.D · Institut de recherches cliniques de Montréal

  • Rémi Rabasa-Lhoret, M.D. Ph.D · Institut de recherches cliniques de Montréal

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-01
Primary Completion
2027-04-01
Completion
2027-05-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07475962 on ClinicalTrials.gov